Correction: Foss et al. The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation. J. Pers. Med. 2022, 12, 692
Kimberly S. Foss, Julianne M. O’Daniel, Jonathan S. Berg, Sabrina N. Powell, Rosemary Jean Cadigan, Kristine J. Kuczynski, Laura V. Milko, Katherine W. Saylor, Megan Roberts, Karen Weck, Gail E. Henderson

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBRCA gene mutations in cancer · Ethics in Clinical Research · Genomics and Rare Diseases
Text Correction
There was an error in the original publication [1] “The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation”.
In the original publication, the authors erroneously reported that the UCSF “Preventative Genomics Clinic” partnered with Color Health, Inc., but it did not.
A correction has been made to Section 3.4.
The paragraph “UCSF partnered with Color Health, Inc. to offer population health screening with institutional support, insurance billing, and available self-pay rates. The current Color Health, Inc. ‘Extended’ test offering includes 74 genes related to cancer, cardiovascular disease, and pharmacogenetics. Clinic providers counsel patients at risk for a hereditary condition based on their personal or family history and, if appropriate, offer screening for preventative health care and family planning. Approximately 40 patients were seen in 2020 for preventative health consultations” was replaced with “UCSF partnered with external clinical labs and their in-house CLIA-certified labs to offer proactive gene panels, pharmacogenetics testing, and carrier screening. Clinic providers counsel patients at risk for a hereditary condition based on their personal or family history and, if appropriate, offer screening for preventative healthcare and family planning. Approximately 40 patients were seen in 2020 for preventative health consultations.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Foss K.S. O’Daniel J.M. Berg J.S. Powell S.N. Cadigan R.J. Kuczynski K.J. Milko L.V. Saylor K.W. Roberts M. Weck K. The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation J. Pers. Med.20221269210.3390/jpm 1205069235629115 PMC 9145687 · doi ↗ · pubmed ↗
